A TRIAL OF MYCOPHENOLATE MOFETIL IN MYASTHENIA GRAVIS

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。这项研究的目的是验证这样一种假设，即在重症肌无力(MG)的初始治疗中，霉酚酸酯(2.5g/d)与泼尼松(20 mg/d)联合使用比单用强的松能更好地控制体征和症状。6个月的开放标签延长将提供关于剂量为2.5-3g/d的MM的安全性和耐受性的进一步信息，并将提供一些关于接受MM维持治疗的患者可以逐渐减少甚至停止使用泼尼松的频率的初步信息。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The goal of this study is to test the hypothesis that mycophenolate mofetil (2.5 g/d) in combination with prednisone (20 mg/d) provides better control of signs and symptoms than prednisone alone in the initial management of myasthenia gravis (MG). A 6 month open-label extension will supply further information about the safety and tolerability of MM at doses ranging from 2.5-3 g/d, and will give some preliminary information about the frequency with which prednisone can be tapered or even discontinued in patients maintained on MM.